ELIQUIS® (apixaban) 2.5 mg & 5 mg Film-coated Tablets

Contraindications:

- Hypersensitivity to active substance or to excipients, active clinically
- Liver function test abnormal. Rare: specific haemorrhage such as brain, intracranial, intraspinal, intramuscular, diaphragmatic, haemorrhoidal, traumatic, post procedural, incision site; haemoptysis, muscle, haematochezia, abdominal pain, hepatic failure.

UNDESIRABLE EFFECTS:

- Concomitant use of Eliquis with antiplatelet agents increases the risk of bleeding. Care with patients with vascular disease, especially those with a history of stroke or transient ischemic stroke: limited experience. Patients with prosthetic heart valves should not receive Eliquis.

DOSAGE:

- Patients with atrial fibrillation and conditions that warrant mono or dual antiplatelet therapy, a careful assessment of the potential benefits against the risk potential should be made before commencement of Eliquis therapy. Use with caution in patients with conditions that act as a risk factor for stroke (e.g., stroke, transient ischemic attack, TIA, or heart failure).

Special warnings and precautions for information on haemodynamically unstable patients, patients with heart failure, patients undergoing coronary revascularization procedures, and patients with severe renal impairment, patients with severe hepatic impairment, patients with severe liver disease, and patients with severe renal disease.

Liver function test abnormal. Rare: specific haemorrhage such as brain, intracranial, intraspinal, intramuscular, diaphragmatic, haemorrhoidal, traumatic, post procedural, incision site; haemoptysis, muscle, haematochezia, abdominal pain, hepatic failure.

Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK).

UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store

432kUK1900560-01; PP-ELI-GBR-5277

ADDITIONAL INFORMATION AVAILABLE ON REQUEST

Bristol-Myers Squibb/Pfizer EEIG, BMS House, Uxbridge Business Marketing Authorisation Number and POM. Marketing Authorisation Holder: Bristol-Myers Squibb/Pfizer EEIG, Uxbridge Business Park, Uxbridge, Middlesex, UB8 1DH.

Local representative in UK: Bristol-Myers Squibb/Pfizer EEIG, HMS House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH.

Local representative in Ireland: Bristol-Myers Squibb/Pfizer EEIG, 55 Bath Road, Portobello, Dublin 4, Ireland.

Local representative in Germany: Bristol-Myers Squibb/Pfizer EEIG, Ilmenauer Platz 1, 14193 Berlin, Germany.

Local representative in Switzerland: Bristol-Myers Squibb/Pfizer EEIG, Basel, Switzerland.

Local representative in France: Bristol-Myers Squibb/Pfizer EEIG, 36 avenue des surroches 1208 Genève, Switzerland.

Local representative in Italy: Bristol-Myers Squibb/Pfizer EEIG, Via B. Marconi 7, 20122, Milano, Italy.

Local representative in Spain: Bristol-Myers Squibb/Pfizer EEIG, C/Estrella del Norte 45, 28035 Madrid, Spain.

Local representative in Portugal: Bristol-Myers Squibb/Pfizer EEIG, Rua de Lisboa, 120, 1000-023 Lisboa, Portugal.

Local representative in Ireland: Bristol-Myers Squibb/Pfizer EEIG, 55 Bath Road, Portobello, Dublin 4, Ireland.

Local representative in Japan: Bristol-Myers Squibb/Pfizer EEIG, Kita 3-1-2, Chuo-ku, Tokyo, 104-0061, Japan.

Local representative in Australia: Bristol-Myers Squibb/Pfizer EEIG, Level 8, 60-62 Market Street, Sydney, NSW 2000, Australia.

Local representative in New Zealand: Bristol-Myers Squibb/Pfizer EEIG, 180 North Quay, Auckland, New Zealand.

Local representative in South Africa: Bristol-Myers Squibb/Pfizer EEIG, 299 Commissioner Street, 2000, Sandton, Johannesburg, South Africa.

Local representative in India: Bristol-Myers Squibb/Pfizer EEIG, 32, Park Village Industrial Park, Plot 123, Sector 123, Gurgaon, Haryana, 122016, India.

Local representative in Singapore: Bristol-Myers Squibb/Pfizer EEIG, 6 Republic Plaza, #30-02, Republic, Singapore 048603.

Local representative in Hong Kong: Bristol-Myers Squibb/Pfizer EEIG, 5/F, East Wing, Exchange Square 2, 8 Finance Street, Central, Hong Kong, China.

Local representative in China: Bristol-Myers Squibb/Pfizer EEIG, 20/F, The Citi Plaza, 153 Honk Kong Road, Wanchai, Hong Kong, China.


Local representative in Thailand: Bristol-Myers Squibb/Pfizer EEIG, Room B3004, The Next Building, 108 Rama 2 Road, Pathumwan, Bangkok 10330, Thailand.

Local representative in Indonesia: Bristol-Myers Squibb/Pfizer EEIG, Unit 24-16, The Heritage Building, Jl. Teuku Umar No. 3-5, Teuku Umar, 12940, Jakarta Pusat, Indonesia.